866-997-4948(US-Canada Toll Free)

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 65 Pages

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2017

Summary

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Integrin beta-3 (3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 20 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Ophthalmology, Cardiovascular, Dermatology, Gastrointestinal and Infectious Disease which include indications Wet (Neovascular / Exudative) Macular Degeneration, Glioblastoma Multiforme (GBM), Breast Cancer, Diabetic Retinopathy, Melanoma, Arterial Thrombosis, Cardiovascular Disease, Diabetic Macular Edema, Diabetic Nephropathy, Ischemic Cerebral Stroke, Lung Cancer, Malabsorption Syndrome, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Pancreatic Cancer, Sepsis and Venous Leg Ulcers (Crural ulcer).

The latest report Integrin Beta 3 - Pipeline Review, H2 2017, outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
- The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Overview
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development
Factor Therapeutics Ltd
Merck & Co Inc
SciFluor Life Sciences LLC
SOM Biotech SL
Vascular Pharmaceuticals Inc
VDDI Pharmaceuticals
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles
A-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-16Y - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cilengitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-0429 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSP-68 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OCU-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proagio - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSF-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RUC-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOM-0777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetraiodothyroacetic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-2690B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xemilofiban hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Products
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Product Development Milestones
Featured News & Press Releases
May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200
Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update
Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update
Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)
Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US
Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board
Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find
May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology
Apr 02, 2016: Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board
Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin av3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200
Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update
Jun 30, 2014: VDDI Provides Update On Xemilofiban
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Factor Therapeutics Ltd, H2 2017
Pipeline by Merck & Co Inc, H2 2017
Pipeline by SciFluor Life Sciences LLC, H2 2017
Pipeline by SOM Biotech SL, H2 2017
Pipeline by Vascular Pharmaceuticals Inc, H2 2017
Pipeline by VDDI Pharmaceuticals, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Dormant Products, H2 2017 (Contd..2), H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *